| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |